Sai Life Sciences Ltd
Sai Life Sciences Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period. Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility.
From Sai Life Sciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period.
- The company plans to achieve EBITDA margins of 28% to 30% within the next couple of years.
- Revenue growth reflects strong momentum across CDMO and CRO businesses, supported by molecule pipeline scaling up and commercial product volume increases.
- FY25 revenue grew 16% YoY, with FY26 expected to continue strong growth momentum and improve from 25% EBITDA margin in FY25 to 28%-30% in next 2 years.
- Capex of about INR700 crores planned for FY26 focused 60-65% on manufacturing and 35% on R&D to support FY27 growth.
2 more points from Sai Life Sciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Sai Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY26, Sai Life Sciences plans capex of close to INR 700 crores.
- Approximately INR 550 crores of this capex is currently planned based on existing visibility, primarily to support fiscal '27 growth.
- INR 50 to 70 crores of capex is earmarked for new modalities including peptides, ADCs, and oligonucleotides.
- The remaining balance capex will be triggered based on business visibility throughout the year.
- Around 60% to 65% of capex will be directed toward manufacturing, and 35% toward R&D.
- Maintenance capex is roughly INR 70 crores.
- New manufacturing capacities came online in November and May, increasing capacity by about 30%.
2 more points from Sai Life Sciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sai Life Sciences sees strong visibility and increased client flow supporting growth despite a softer global CRDMO environment. (Page 15)
- Demand is driven primarily by supply chain shifts and long-standing client relationships. (Page 15)
- The company has observed significant traction in both process development and manufacturing with several molecules scaling up, which is fueling capex expansion. (Pages 9, 10, 15)
- Current manufacturing capacity utilization is high (~67% in FY25) with a 30% capacity increase expected from new lines coming online between November and May. (Page 6)
2 more points from Sai Life Sciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Sai Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Sai Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Life Sciences Ltd Q4 FY25 results?
Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period. Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility.
What is Sai Life Sciences Ltd share price analysis?
Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 83.4 with a market cap of ₹29,600 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life Sciences Ltd planning capital expenditure?
For FY26, Sai Life Sciences plans capex of close to INR 700 crores.
Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.